Medtech Deals In Depth: November 2021
Executive Summary
Major medtech deals in November include Coloplast's $2.5bn acquisition of Atos Medical and Alcon's deal for Ivantis.
You may also be interested in...
Deals In Depth: April 2022
In the top April alliance by deal value, Jazz Pharmaceuticals acquired exclusive global development and commercialization rights to Werewolf Therapeutics' WTX-613. Preclinical WTX-613 is an engineered IFN⍺2b cytokine pro-drug that is activated specifically within the tumor microenvironment where it can stimulate IFNα receptors on cancer-fighting immune effector cells. Jazz expects to submit an IND application to the FDA for WTX-613 in 2023. Jazz paid $15M up front and Werewolf is eligible to receive development, regulatory and commercial milestone payments of up to $1.26bn, plus royalties.
Dealmaking Quarterly Statistics, Q1 2022
During Q1, biopharma merger and acquisition value reached $9.9bn and drew in $51.2bn in potential deal value from alliances. Device company M&A values reached $4.6bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $52.5m.
Financing Quarterly Statistics, Q1 2022
During Q1, biopharmas brought in an aggregate $17.9bn in financing and device company fundraising totaled $2.2bn; while in vitro diagnostic firms and research tools players raised $1.5bn.